Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade
AffiliationUniv Arizona, Coll Med
Univ Arizona, Coll Med, Banner Univ, Med Ctr Tucson, Dept Dermatol & Oncol
KeywordsAdverse drug reaction
Hypertrophic lichen planus
Programmed cell death ligand 1
Squamous cell carcinoma
MetadataShow full item record
CitationMyrdal, C. N., Sundararajan, S., & Curiel-Lewandrowski, C. (2020). Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade. Case Reports in Dermatology, 12(2), 119-123.
JournalCASE REPORTS IN DERMATOLOGY
Rights© 2020 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractHypertrophic lichen planus (HLP) may not have the typical histological findings of lichen planus and often mimics squamous cell carcinoma (SCC). Distinguishing between the two can pose a diagnostic challenge. Here, we present a case of eruptive HLP mimicking SCC in the context of programmed cell death ligand 1 (PD-L1) immune checkpoint inhibition. A 73-year-old woman recently treated with durvalumab, an anti-PD-L1 antibody, presented to our clinic with diffuse hyperkeratotic papules and plaques previously thought to be eruptive SCC. The lesions did not respond to topical fluorouracil and continued to appear despite discontinuation of immunotherapy. Further histological analysis revealed intraepidermal epithelial proliferation with lichenoid inflammation. Subsequent treatment with topical corticosteroids significantly improved the size and number of lesions. The diagnosis of HLP was made based on histological features and response to topical steroids in the context of recent immunotherapy. This case reveals HLP as a potential adverse effect of PD-L1 inhibition and highlights the need for additional diagnostic assessment in patients presenting with eruptive hyperkeratotic lesions, especially on the lower extremities.
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as © 2020 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).
- Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy.
- Authors: Ameri AH, Foreman RK, Vedak P, Chen S, Miller DM, Demehri S
- Issue date: 2020 May
- Hypertrophic Lichen Planus Mimicking Verrucous Lupus Erythematosus.
- Authors: Riahi RR, Cohen PR
- Issue date: 2018 Nov 6
- Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma.
- Authors: Fontecilla NM, Kittler NW, Lopez A, Yang C, Geskin L
- Issue date: 2018 Aug
- Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
- Authors: Cardis MA, Jiang H, Strauss J, Gulley JL, Brownell I
- Issue date: 2019 Jun 4
- Widely metastatic squamous cell carcinoma originating from malignant transformation of hypertrophic lichen planus in a 24-year-old woman: case report and review of the literature.
- Authors: Tong LX, Weinstock MJ, Drews R, Sheikine Y, Kim CC
- Issue date: 2015 May-Jun